AbbVie Strengthens Evidence For Rinvoq In Crohn's
Executive Summary
Over 10 datasets presented at Digestive Disease Week strengthen the case that clinicians should view AbbVie’s selective JAK inhibitor Rinvoq as a powerful addition to their clinical toolbox for moderate-to-severe Crohn’s disease patients. However, safety concerns will keep it as second-line treatment in the US after its likely label expansion this month.